ATYR.O (ATYR.O) News
Track canonical SquawkNews coverage tagged to ATYR.O, ATYR.O. This hub brings together deduplicated headlines about market instrument, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
BRIEF — aTyr Pharma Announces Alignment With FDA On Phase 3 Study Of Efzofitimod In Pulmonary Sarcoidosis
Sept 24 (Reuters) — aTyr Pharma Inc: Atyr Pharma Announces Alignment With Fda On Phase 3 Study Of Efzofitimod In Pulmonary Sarcoidosis Atyr Pharma - To Initiate Study-related Activities In Q4 2026 Source text:... Further
REGULATION | Sep 24, 2026, 10:01 AM UTC
L
aTyr Pharma aligns with FDA on Phase 3 efzofitimod trial in pulmonary sarcoidosis
aTyr Pharma aligned with the FDA on a Phase 3 efzofitimod trial in chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. Study-related activities are expected to start in Q4 2026 as the company prepar
REGULATION | Sep 24, 2026, 10:01 AM UTC